1. EGFR mutation status in brain metastases of non-small cell lung carcinoma

   • Fanny Burel-Vandenbos
   • Damien Ambrosetti
   • Florence Pedeutour

   Topic Review 20 October 2012 Pages: 1 - 10

   

2. The role of LAT1 in ¹⁸F-DOPA uptake in malignant gliomas

   • Ryan S. Youland
   • Gaspar J. Kitange
   • Jann N. Sarkaria

   Laboratory Investigation 20 October 2012 Pages: 11 - 18

   

3. Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma

   • Kevin Petrecca
   • Marie-Christine Guiot
   • Luis Souhami

   Clinical Study 10 October 2012 Pages: 19 - 23

   

4. Post-treatment T1 shortening in primary CNS lymphoma

   • Sasan Karimi
   • Vaios Hatzoglou
   • Lisa M. Deangelis

   Clinical Study 17 October 2012 Pages: 25 - 31

   

5. A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806)

   • Brian M. Alexander
   • Meihua Wang
   • Minesh P. Mehta

   Clinical Study 20 October 2012 Pages: 33 - 39

   

6. Continuous daily sunitinib for recurrent glioblastoma

   • Teri Nguyen Kreisl
   • Perry Smith
   • Howard A. Fine

   Clinical Study 20 October 2012 Pages: 41 - 48

7. Factors affecting peritumoral brain edema in meningioma: special histological subtypes with prominently extensive edema

   • Tadashi Osawa
   • Masahiko Tosaka
   • Yuhei Yoshimoto

   Clinical Study 27 October 2012 Pages: 49 - 57

   

8. Anaplastic PXA in adults: case series with clinicopathologic and molecular features

   • Yao Schmidt
   • B. K. Kleinschmidt-DeMasters
   • Denise Damek

   Clinical Study 25 October 2012 Pages: 59 - 69

   

9. MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas

   • Simon Kjær Hermansen
   • Rikke Hedegaard Dahlrot
   • Bjarne Winther Kristensen

   Clinical Study 28 October 2012 Pages: 71 - 81

   

10. Epilepsy in the end-of-life phase in patients with high-grade gliomas

    • Andrea Pace
    • Veronica Villani
    • Carmine Maria Carapella

    Clinical Study 20 October 2012 Pages: 83 - 86

11. Outcome of discontinuing bevacizumab prior to malignant glioma progression

    • Wendy J. Sherman
    • Jeffrey J. Raizer
    • Sean A. Grimm

    Letter to the Editor 12 October 2012 Pages: 87 - 89

12. Acknowledgement of reviewers 2011

    Acknowledgement 29 November 2012 Pages: 91 - 94

13. Erratum to: The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas

    • T. A. Juratli
    • M. Kirsch
    • D. Krex

    Erratum 27 November 2012 Pages: 95 - 95